Davunetide
- Generic Name
- Davunetide
- Drug Type
- Small Molecule
- Chemical Formula
- C36H60N10O12
- CAS Number
- 211439-12-2
- Unique Ingredient Identifier
- GF00K3IIWE
- Background
Davunetide has been used in trials studying the treatment of Progressive Nonfluent Aphasia, Progressive Supranuclear Palsy, Predicted Tauopathies, Including, Corticobasal Degeneration Syndrome, and Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17.
Davunetide is the first drug to improve memory performance by impacting the mechanisms that lead to physical damage in the brain caused by neurofibrillary tangles, one of the two established pathological hallmarks that are common to amnestic mild cognitive impairment (aMCI) and Alzheimer's disease (AD). Davunetide is derived from a naturally occurring neuroprotective brain protein known as activity dependent neuroprotective protein.
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2013-01-17
- Lead Sponsor
- Allon Therapeutics
- Target Recruit Count
- 313
- Registration Number
- NCT01110720
- Locations
- 🇺🇸
Mayo Clinic, AZ, Scottsdale, Arizona, United States
🇺🇸UMDNJ - Robert Wood Johnson Medical Center, New Brunswick, New Jersey, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Davunetide (AL-108) in Predicted Tauopathies - Pilot Study
- Conditions
- Predicted Tauopathies, IncludingProgressive Supranuclear PalsyFrontotemporal Dementia With Parkinsonism Linked to Chromosome 17Corticobasal Degeneration SyndromeProgressive Nonfluent Aphasia
- Interventions
- Drug: Placebo nasal spray
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 12
- Registration Number
- NCT01056965
- Locations
- 🇺🇸
University of California, San Francisco (UCSF), San Francisco, California, United States
A Multicenter Study of NAP (AL-108) in Schizophrenia
- First Posted Date
- 2007-07-23
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 63
- Registration Number
- NCT00505765
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸Maryland Psychiatric Research Center, Catonsville, Maryland, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment
- Conditions
- Mild Cognitive Impairment, So Stated
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2012-10-24
- Lead Sponsor
- Allon Therapeutics
- Target Recruit Count
- 144
- Registration Number
- NCT00422981
- Locations
- 🇺🇸
Pivotal Research, Peoria, Arizona, United States
🇺🇸Clinical Neuroscience Solutions, Inc, Memphis, Tennessee, United States
🇺🇸Clinical Neuroscience Solutions, Orlando, Florida, United States
Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery
- First Posted Date
- 2006-11-27
- Last Posted Date
- 2012-10-24
- Lead Sponsor
- Allon Therapeutics
- Target Recruit Count
- 234
- Registration Number
- NCT00404014
- Locations
- 🇺🇸
Cardiac and Thoracic Surgical Associates, Ltd., Mechanicsville, Virginia, United States
🇺🇸Clinical Cardiovascular Research Center, Dallas, Texas, United States
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.